Pfizer CentreOne Header Pfizer CentreOne Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Unicycive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Unicycive Therapeutics Acquires Renazorb from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in CKD Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"},{"orgOrder":0,"company":"Unicycive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Lanthanum Carbonate

    Menu

    Lanthanum Carbonate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Unicycive Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

              Details:

              Renazorb (Lanthanum Dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. it is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.

              Lead Product(s): Lanthanum Carbonate

              Therapeutic Area: Nephrology Product Name: Renazorb

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Spectrum Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Unicycive Therapeutics Acquires Renazorb from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in CKD Patients

              Details:

              Under the terms of the asset purchase agreement, Unicycive has acquired global rights for Renazorb and all its trademark and associated patents, and Spectrum has received an equity interest in Unicycive along with milestone and royalty payments.

              Lead Product(s): Lanthanum Carbonate

              Therapeutic Area: Nephrology Product Name: Renazorb

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Unicycive Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition December 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Evonik
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY